企業プロフィール
BriaCell 株価・ニュース・カタリスト
- ティッカー:
- BCTX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Canada
株価パフォーマンス
4.11 USD (-3.97%)
終値
最終更新: 2026年10月1日
23.7M USD
時価総額
株価変動の要因
2026年10月1日 時点で BCTX は 3.97% 下落し、$4.11 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Cancer Immunotherapy Developer
BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents.
Bria-IMT in Metastatic Breast Cancer
Bria-IMT is an off-the-shelf whole-cell immunotherapy being evaluated with checkpoint blockade in metastatic breast cancer. The program has advanced into a pivotal Phase 3 study for patients who have exhausted multiple prior treatment options.
Personalized Off-the-Shelf Platform
The Bria-OTS and Bria-BRES approaches use a bank of engineered cell lines selected according to patient immune characteristics. This design seeks to preserve personalization while avoiding the manufacturing time required for fully patient-specific cell therapies.
Bria-BRES and Bria-PROS Expansion
Bria-BRES is being developed for breast cancer through a next-generation clinical program, while Bria-PROS extends the platform into prostate cancer. These programs broaden the company's pipeline beyond the lead Bria-IMT regimen.
Combination-Oriented Development
BriaCell's strategy is to pair its cellular immunotherapies with checkpoint inhibitors and other agents that may reinforce antitumor immune activity. The company retains responsibility for clinical development while using external manufacturing and clinical partners.
Biomarker-Guided Patient Selection
Clinical and translational work evaluates immune signatures and tumor characteristics associated with response. These biomarkers may help define the patients most likely to benefit from BriaCell's cellular regimens.
今後のカタリスト
- Initiation of the Phase 1/2a study of Bria-BRES+ following FDA clearance of the IND.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。